ORIC Pharmaceuticals, Inc. (ORIC)

ORIC Pharmaceuticals, Inc. is trading at $9.24, up 2.78% on the session. The 50 day average sits at $12.46 and the 200 day at $11.14, which puts the stock in a uptrend. RSI is at 32.9, which reads as weak, and MACD is bearish crossover. Volume is above average.

The nearest support is around $8.28 with resistance near $14.00, so that band frames the current range. Average daily movement is roughly $1.03, or about 11.1% of the share price, which is what any stop placement has to allow for. The overall health score of 25 out of 100 combines a trend score of 33, momentum of 20 and a risk score of 18.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.